Increasing the value of research in palliative care
What is the value of the research that we do? What is the calibre of the evidence that we generate? Most importantly, are we making a difference for patients and society through this research?
Research is necessary to improve clinical care. But what proportion of research carried out achieves this goal? The annual global investment in biomedical research reached US$240 billion in 2010. 1 Rather extraordinarily, it is estimated that around 85% of this investment may be wasted. 2 As explored in a 2014 The Lancet series, this waste occurs at several stages: (1) when the wrong question is asked, (2) when an inappropriate study design is used, (3) through inefficient research regulation and management, (4) through biased under-reporting of data, and (5) when research reports are unusable by clinicians. 3 Within palliative care, the volume of research being carried out has increased dramatically over the past decades. But how much of this research translates into meaningful impacts for society? And how much would, according to The Lancet criteria, be considered wasted?
Are we asking the right questions? A National Institute of Health (USA) report on palliative care research trends and funding showed that while the number of research publications tripled between 1997 and 2010, gaps in important topic areas were identified. 4 For example, two out of three of all publications concerned cancer, and few reflected the growing needs of patients with complex and multiple chronic conditions, health economics, or education and training.
More recently in the United Kingdom, the Neuberger review highlighted specific gaps in evidence relating to palliative care in general and the Liverpool Care Pathway in particular. 5 In response, the National Institute for Health Research (UK) has commissioned a mapping of evidence requirements in palliative and end-of-life care. The James Lind Alliance Priority Setting Partnership has also been established to find out what palliative and end-of-life care research is important to people who are likely to be within the last years of life, and their families and carers, to inform the future research. These and similar initiatives should help to reduce waste from research that addresses low-priority questions.
Are we using the correct study design? Problems relating to research methodology are intrinsically related to the research workforce, and in palliative care, there is a serious shortage of skilled researchers able to lead research and train others. For example, in 2008, there were fewer than 40 UK academics with major commitments to palliative and end-of-life care as judged through the Research Excellence Framework. 6 Anecdotally, there are fewer professors of palliative medicine in the whole of the United Kingdom than there are professors of oncology at the Royal Marsden Hospital in London. Adequate training of clinical researchers in study design and methodology is essential to avoid producing misleading or flawed results. At a minimum, this should include access to postgraduate courses on research methods for palliative care. The involvement of statisticians and methodologists in all research studies is desirable and particularly important for intervention studies. 7 The proportion of studies that achieve this is unclear.
Research regulation and governance can be burdensome, particularly in palliative care where patients are often frail and potentially vulnerable. It is not an uncommon perception that it is unethical to involve people with palliative care needs in research. This can result in important research questions being overlooked, or research being underpowered, leading to waste. However, the recent MORECare study provided unanimous support that it is ethically desirable for patients and families with palliative care needs to be offered the opportunity to be involved in research. Internationally relevant recommendations to overcome some of the ethical challenges were produced, including the creation of research ethics networks for palliative and end-of-life care to disseminate best practice. 8 Where research is completed, how much remains unpublished or under-reported? Non-dissemination of research leads to bias, unnecessary duplication of studies and harms patient outcomes; yet, around half of all healthrelated studies are unreported. It is likely that biased underreporting of studies exists in the palliative care literature too. For example, only 43% of abstracts presented at the European Association of Palliative Care congress in 2005 eventually made it to peer-reviewed publication. 9 What is less clear is the extent to which there is biased reporting of data within studies. Academic success is currently judged on the basis of grant income and high-impact 556718P MJ0010.1177/0269216314556718Palliative MedicineEditorial editorial2014 Editorial Palliative Medicine 28 (10) publication, and this can lead to a danger of selective reporting, for example, publishing only positive results. Full dissemination, including not only research protocols and full study reports but also participant-level datasets for use by external researchers, would reduce waste and improve patient outcomes. This could be achieved through the development by funders and academic institutions of performance metrics that reflect full dissemination of research, including availability of original datasets. 10 For data that are published, what proportion will make it to practice? Of the articles in this edition of Palliative Medicine, how many will be read, interpreted, and used by clinicians to improve patient care? The academic publishing process has been criticised for generating articles aimed at journal editors and peer reviewers, rather than the clinicians who might use the data. Publication of data should be seen as the means, not the end, and journals are starting to adopt innovative approaches such as podcasts, blogs and use of social media to improve accessibility of research evidence. The brief summaries now included with research articles in this journal are a step in the right direction.
What factors determine whether or not research evidence is translated by clinicians and policy-makers into practice? Implementation science, the exploration of factors that contribute to successful implementation of research findings, is a growing field but has been relatively little studied in palliative care. It is essential that our research investigates not just what works in theory, but what works in practice. Initiatives underway to address this include the Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South London, which will bring together researchers, clinicians, policymakers and patients/families to address translational gaps in palliative and end-of-life care, with recommendations of national and international relevance. 11 Increasing the value of research in palliative care requires investment. Of the US$5 billion spent by the National Cancer Institute (USA) on research in 2010, just 1% was awarded to palliative care research. 12 In the United Kingdom, less than 0.5% of cancer research funding is allocated to palliative and end-of-life care research, and in 2010, this was allocated in 48 separate awards, providing an average of just £25,000 per award. The danger of this piecemeal approach to palliative care funding is to produce a mass of small-scale studies that have little impact, while national policies are developed without an adequate evidence base.
It is essential that we use the research funding we have wisely and target questions that must be answered rather than simply those that can be answered. Research reporting needs to be transparent and complete, and provided in a way that can be readily used by clinicians to improve patient, family and societal outcomes. It is likely that in palliative care, as in other specialties, considerable waste of resources occurs. We need to scrutinise the research that we do, and understand and quantify its inefficiencies, in order to make the most difference for society.
